MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Becton Dickinson and Co

Închisă

SectorSănătate

226.59 0.3

Rezumat

Modificarea prețului

24h

Curent

Minim

222.83

Maxim

226.69

Indicatori cheie

By Trading Economics

Venit

-118M

303M

Vânzări

-272M

5.2B

P/E

Medie Sector

38.627

63.778

EPS

3.43

Randament dividend

1.74

Marjă de profit

5.863

Angajați

70,000

EBITDA

-1.3B

453M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+21.16% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.74%

2.39%

Următoarele câștiguri

1 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-6.1B

66B

Deschiderea anterioară

226.29

Închiderea anterioară

226.59

Sentimentul știrilor

By Acuity

28%

72%

83 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Becton Dickinson and Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 feb. 2025, 22:09 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business

7 nov. 2024, 12:59 UTC

Câștiguri

Becton Dickinson Profit Rises as Acquisition Buoys Sales - Update

7 nov. 2024, 12:56 UTC

Câștiguri

Becton Dickinson Fiscal 4Q Profit Rises as Acquisition Buoys Sales

1 aug. 2024, 11:08 UTC

Câștiguri

Becton 3Q Adjusted Earnings Top Views But International Sales Weigh on FY24 Outlook

3 iun. 2024, 11:18 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash

5 feb. 2025, 21:56 UTC

Câștiguri

Correct: Becton Dickinson Sees 2025 Adj EPS $14.30-Adj EPS $14.60 >BDX

5 feb. 2025, 21:54 UTC

Câștiguri

Becton Dickinson Sees 2025 EPS $14.30-EPS $14.60 >BDX

5 feb. 2025, 21:54 UTC

Câștiguri

Becton Dickinson Sees 2025 GAAP Rev Growth 7.9% to 8.4% >BDX

5 feb. 2025, 21:53 UTC

Câștiguri

Becton Dickinson Sees 2025 Rev $21.7B-$21.9B >BDX

5 feb. 2025, 21:30 UTC

Câștiguri

Becton Dickinson 1Q Adj EPS $3.43 >BDX

5 feb. 2025, 21:30 UTC

Câștiguri

Becton Dickinson 1Q Rev $5.2B >BDX

5 feb. 2025, 21:30 UTC

Câștiguri

Becton Dickinson 1Q Net $303M >BDX

5 feb. 2025, 21:30 UTC

Câștiguri

Becton Dickinson 1Q EPS $1.04 >BDX

7 nov. 2024, 11:36 UTC

Câștiguri

Becton Dickinson Sees FY25 Rev $21.9B-$22.1B >BDX

7 nov. 2024, 11:35 UTC

Câștiguri

Becton Dickinson Sees FY25 Adj EPS $14.25-Adj EPS $14.60 >BDX

7 nov. 2024, 11:30 UTC

Câștiguri

Becton Dickinson 4Q EPS $1.45 >BDX

7 nov. 2024, 11:30 UTC

Câștiguri

Becton Dickinson 4Q Adj EPS $3.81 >BDX

7 nov. 2024, 11:30 UTC

Câștiguri

Becton Dickinson 4Q Rev $5.4B >BDX

7 nov. 2024, 11:30 UTC

Câștiguri

Becton Dickinson 4Q Cont Ops EPS $1.45 >BDX

1 aug. 2024, 10:37 UTC

Câștiguri

Becton Dickinson Now Sees FY24 Revenue About $20.1B; Had Seen $20.1B-$20.3B >BDX

1 aug. 2024, 10:35 UTC

Câștiguri

Becton Dickinson Sees FY24 Revenue Up About 3.7%, Organic Revenue Up 5%-5.25% >BDX

1 aug. 2024, 10:35 UTC

Câștiguri

Becton Dickinson Sees FY24 Adj EPS $13.05-Adj EPS $13.15 >BDX

1 aug. 2024, 10:30 UTC

Câștiguri

Becton Dickinson 3Q EPS $1.68 >BDX

1 aug. 2024, 10:30 UTC

Câștiguri

Becton Dickinson 3Q Net $487M >BDX

1 aug. 2024, 10:30 UTC

Câștiguri

Becton Dickinson 3Q Adj EPS $3.50 >BDX

1 aug. 2024, 10:30 UTC

Câștiguri

Becton Dickinson 3Q Rev $5B >BDX

4 iun. 2024, 17:26 UTC

Achiziții, Fuziuni, Preluări

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3 iun. 2024, 15:30 UTC

Acțiuni populare

Stocks to Watch Monday: GameStop, AMC, Paramount, Nvidia -- WSJ

3 iun. 2024, 13:26 UTC

Achiziții, Fuziuni, Preluări

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3 iun. 2024, 12:25 UTC

Top știri
Achiziții, Fuziuni, Preluări

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

Comparație

Modificare preț

Becton Dickinson and Co Așteptări

Obiectiv de preț

By TipRanks

21.16% sus

Prognoză pe 12 luni

Medie 273.88 USD  21.16%

Maxim 280 USD

Minim 260 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBecton Dickinson and Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

8

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

225.12 / 227.935Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

83 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.